FRA
CELG

Front Row Advisors’s Celgene Corp CELG Stock Holding History

Front Row Advisors’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-58
Closed -$5K – 1072
2019
Q2 		$5K Hold
58
– – ﹤0.01% 614
2019
Q1 		$5K Hold
58
– – ﹤0.01% 617
2018
Q4 		$4K Hold
58
– – ﹤0.01% 635
2018
Q3 		$4 Hold
58
– – ﹤0.01% 652
2018
Q2 		$5 Sell
58
-442
-88% -$36.7K ﹤0.01% 640
2018
Q1 		$45K Buy
500
+200
+67% +$19.2K 0.03% 235
2017
Q4 		$31K Buy
+300
New +$33.9K 0.02% 288

Other funds holding CELG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Front Row Advisors's CELG Position: Q3 2019 in Review

Front Row Advisors sold out of Celgene Corp (CELG) in Q3 2019, closing a stake of 58 shares — an estimated $5K sold.

Front Row Advisors first reported a position in CELG in Q4 2017 and held it in 7 quarters. The position peaked at $45K in Q1 2018. 1,245 funds tracked by Wall St. Rank hold CELG as of Q3 2019.

  • Front Row Advisors reported no remaining Celgene Corp position as of Q3 2019 after selling out during the quarter.
  • Front Row Advisors sold 58 Celgene Corp shares in Q3 2019, an estimated $5K.
  • Front Row Advisors first reported a position in Celgene Corp in Q4 2017 and held it in 7 quarters.
  • Front Row Advisors's Celgene Corp position peaked at $45K in Q1 2018.
  • 1,245 funds tracked by Wall St. Rank held Celgene Corp as of Q3 2019.

Based on Front Row Advisors's 13F filing for Q3 2019, filed 8 Nov 2019.